Scribd Logo
Upload

Welcome to Scribd!

  • 708 views

    Linagliptin - DRUG STUDY

    Uploaded by

    Acads use
    Linagliptin is a DPP-4 inhibitor indicated for treatment of type 2 diabetes. It works by inhibiting the enzyme DPP-4, which degrades the incretin hormones GLP-1 and GIP. Linagliptin is contraindicated in patients with a history of hypersensitivity and should be discontinued if signs of pancreatitis develop. Nurses should monitor patients treated with linagliptin for hypoglycemia and pancreatitis.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Linagliptin - DRUG STUDY

    Uploaded by

    Acads use
    708 views1 page
    Linagliptin is a DPP-4 inhibitor indicated for treatment of type 2 diabetes. It works by inhibiting the enzyme DPP-4, which degrades the incretin hormones GLP-1 and GIP. Linagliptin is contraindicated in patients with a history of hypersensitivity and should be discontinued if signs of pancreatitis develop. Nurses should monitor patients treated with linagliptin for hypoglycemia and pancreatitis.

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Linagliptin is a DPP-4 inhibitor indicated for treatment of type 2 diabetes. It works by inhibiting the enzyme DPP-4, which degrades the incretin hormones GLP-1 and GIP. Linagliptin is contraindicated in patients with a history of hypersensitivity and should be discontinued if signs of pancreatitis develop. Nurses should monitor patients treated with linagliptin for hypoglycemia and pancreatitis.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    708 views1 page

    Linagliptin - DRUG STUDY

    Uploaded by

    Acads use
    Linagliptin is a DPP-4 inhibitor indicated for treatment of type 2 diabetes. It works by inhibiting the enzyme DPP-4, which degrades the incretin hormones GLP-1 and GIP. Linagliptin is contraindicated in patients with a history of hypersensitivity and should be discontinued if signs of pancreatitis develop. Nurses should monitor patients treated with linagliptin for hypoglycemia and pancreatitis.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 1

    DRUG STUDY

    Generic Name Classification and Indication Mechanism of Contraindications Side effects Nursing Considerations
    Linagliptin Category action
    Brand Name  Observe patient for
    Trajenta A. Chemical: Indicated for the Linagliptin in is contraindicated in severe or signs and symptoms of
    dipeptidyl treatment of an inhibitor of patients with a history ongoing pain in hypoglycemic reactions
    peptidase-4 (DPP- type II diabetes DPP-4, an of hypersensitivity to your joints; (abdominal pain,
    Available dosage
    4) inhibitor in addition to enzyme that linagliptin, such as a severe sweating, hunger,
     5mgOD diet and degrade s the anaphylaxis, urticaria, autoimmune weakness, dizziness,
    B. Therapeutic: anti- exercise. incretin angioedema, reaction-- headache, tremor,
    hyperglycemic hormones exfoliative dermatitis itching, blisters, tachycardia, anxiety).
    drugs glucagon-like or other serious breakdown of  Monitor for signs of
    peptide-1 (GLP- allergic skin the outer layer pancreatitis (nausea,
    1) and glucose condition (serious of skin; or. vomiting, anorexia,
    depend ent rash), or bronchial symptoms of persistent severe
    insulino tropic hypersensitivity. heart failure-- abdominal pain,
    polypep tide shortness of sometimes radiating to
    Route PO (GIP). breath (even the back) during
    Frequency OD while lying therapy. If pancreatitis
    down), swelling occurs, discontinue
    Pharmacokinetics in your legs or linagliptin and monitor
     Onset: 1 hour feet, rapid serum and urine
     Peak: 1.5 hours weight gain. amylase,
     Duration: 12 hours amylase/creatinine
     Half Life: 100-155 clearance ratio,
    hours electrolytes, serum
    calcium, glucose, and
    lipase

    You might also like